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Summary
The intravenous sensitization of C57BL/6 (B6) mice with class I H-2-disparate B6-C-H-26'°1
(bml) spleen cells resulted in the abrogation of CD8+ T cell-mediated anti-bml (proliferative
and interleukin 2-producing) T helper (Th) cell activities. In vitro stimulation of lymphoid cells
from these mice with bml cells, however, generated a reduced, but appreciable, anti-bml cytotoxic
T lymphocyte (CTL) response. Moreover, the anti-bml CTL response, upon stimulation with
[bml x B6-C-H-26-12 (bm12)]F1 spleen cells, was enhanced when compared with the response
induced upon stimulation with bml cells. These in vitro results were reflected on in vivo graft
rejection responses; bml skin grafts engrafted in the bml-presensitized B6 mice exhibited prolonged
survival, whereas (bml x bm12)F1 grafts placed collateral to bml grafts (dual engrafted mice)
inhibited the tolerance to bml. In the B6 mice 1-2 d after rejecting the bml grafts, anti-bml
Th activities remained marginal, whereas potent anti-bml CTL responses were found to be generated
from their spleen cells. Administration in vivo of anti-CD4 antibody into bml-presensitized,
dual graft-engrafted mice prolonged bml graft survival and interfered with enhanced induction
of anti-bml CTL activity. These results indicate that anti-class I alloantigen (bml) tolerance
as induced by intravenous presensitization with the relevant antigens is not ascribed to the elimination
of CD8+ CTL precursors, but to the specific inactivation of CD8+ Th cells, whose function
can be bypassed by activating third-party Th cells.
mmune responses to alloantigens are initiated by the rec-
ognition of alloantigens by Th cells. Recent studies have
revealed the existence of Th subsets that are different in their
phenotypes and mode of alloantigen recognition (1-3). Var-
ious subsets of Th cells are, thus, considered to initiate anti-
allo-immune responses. The overall anti-allo-immune responses
consist of a complicated network in which different subsets
ofT cells, macrophage/APC, and B cells participate. Rosen-
berg et al. (4) showed that allograft rejection results from
interactions especiallybetween T cells ofdifferent phenotypes,
or of different antigen specificities, and with distinct func-
tions. It would be of importance to consider this when an
immune manipulation is attempted to induce the tolerance
of anti-allo-immune responses.
The presentation of alloantigens via an intravenous route
regulates positively or negatively the induction of anti-allo-
immune responses, as has been reported for the effect ofdonor-
specific transfusion (DST)' (5-15). Earlier studies from our
1 Abbreviations used in this paper . DST, donor-specific transfusion; FMF,
flow microfluorometry; MLR, mixed lymphocyte reaction; SN,
supernatant.
laboratory have demonstrated that anti-allo-H-2 antigen toler-
ance, which leads to prolonged graft survival, is inducible
by intravenous presensitization with cells expressing the cor-
responding allo-H-2 antigens (16-18). This was, however,
achieved in two simplified donor-hostcombinations with ei-
ther class I (16, 17) or class II (18) H-2 disparity. Since en-
grafting allogeneic tissue with complex disparity induces re-
jection responses involving complicated cellular interactions,
it will be required to investigate how an anti-allo T cell re-
sponse is influenced by other T cell responses. Such an inves-
tigation could contribute to initiating the establishment of
anti-allo-tolerance in the donor-host combinations with a com-
plex disparity.
The present study was undertaken to investigate how anti-
allo-class I H-2 tolerance is influenced when third-party Th
function is introduced by engrafting a class I and class II
H-2-disparate graft. The results demonstrate that intravenous
presensitization ofB6 mice with bml cells induced the abro-
gation of anti-bml Th activity and the prolongation ofbml
skin graftsurvival. However, when bml-presensitized B6 mice
were engrafted with a (bml x bm12)F1 skin graft collateral
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the (bml x bm12)Ft graft without exhibiting its prolonged
survival. It is also shown that unprolongation of bml graft
survival in bml-presensitized B6 mice engrafted with dual
skin grafts is associated with enhanced generation of anti-
bmlCTLactivity, andpreventedby in vivo injection of anti-
CD4 antibody.
Materials and Methods
Mice.
￿
C57BL/6 (B6) and BALB/c mice were purchased from
Shizuoka Experimental Animal Laboratory. B6-C-H-211'"1 (bml)
andB6-C-H-26°'12 (bm12) mice were originally provided by D.H.
Sachs(NationalCancer Institute, Bethesda, MD).Thesetwostrains
of mutant mice and theirhybrid (bml x bm12)F1 mice were bred
by mating in ourlaboratory. These mice were used forexperiments
at 7-9 wk of age. Female mice were used throughout this study
except for donor mice of grafts in some experiments.
Intravenous Presensitization with Allogeneic Cells.
￿
Mice were in-
jected with 10' allogeneic bml spleen cells intravenously.
Media Usedfor In Vitro Cell Culturing.
￿
Culture medium used
for the mixed lymphocyte reaction (MLR) was RPMI 1640 sup-
plemented with 10% horse serum, 5 x 10-5 M 2-ME, sodium
pyruvate, glutamine, nonessential amino acids, and 5 mM hepes
buffer. Complete medium for thegeneration ofCTL wasprepared
by replacing10% horse serumwith 10% FCSin theabove medium.
RPMI 1640 supplemented with 5% FCS plus 5 x 10-5 M 2-ME
was used for the production of IL2 and IL2 assays.
mAbs.
￿
Anti-L3T4(GK1.5) (19) and anti-Lyt-2 (3.155) (Amer-
ican Type CultureCollection, Rockville, MD)mAbs were obtained
from culture supernatants of hybridomas producing the relevant
antibody. GK1.5 mAb wasalso obtained in aform of ascitic fluid.
Gammaglobulin fraction of theascitic fluidwasobtained by precipi-
tation at 50% saturation with ammonium sulfate and used forin
vivo administration.
Treatment of Lymphoid Cells with Antibody Plus Complement
(C). Spleen or lymph node cells (108) were incubated at 4°C for
30 min with appropriate dilutions of anti-L3T4 or -Lyt-2 mAb.
Cells were washed and incubated at 37°C for 45 min with rabbit
Cpreabsorbed with syngeneicmousespleen cellsat afinaldilution
of 1:20. The efficacy ofthese antibody treatments was confirmed
in flow microfluorometric analysis by demonstrating that the treat-
ment with anti-L3T4 or -Lyt-2 antibody results in almost com-
plete elimination ofthe respective Lyt-2' (CD8+) or L3T4* (CD4+)
T cell subset without damage onto the other alternative T cell
subset.
MLR.
￿
The responding lymph node or spleen cells, obtained
from a pool of three to five animals per group, were resuspended
in complete medium and cultured at a concentration of 2 x 105
cells per culture well together with 4 x 105 irradiated (2,000 rad)
stimulating spleen cells in a total volume of 0.2 ml (16-18). Each
MLR was performed in triplicate in flat-bottomed microculture
plates (25860; CorningGlassWorks, Coming, NY)andmaintained
in a humidified atmosphere at 5% C02 at 37°C. The cultures
were harvested at 96 h after an 8-h pulse with 20 KBq/well of
[3H]TdR by using an automatic cell harvester onto glass fiber
filters. Radioactivity was determined by liquid scintillation spec-
trometry. Results were calculated from uptake of [3H]TdRand ex-
pressed as the mean uptake in cpm ± SE of triplicate cultures.
Generation ofCTL.
￿
TheCTLinduction in macrocultures was
performed as previously described (20). Briefly, 5 x 106 lymph
node or spleen cells were cultured in vitro with 106 irradiated
106 Graft Rejection by Cell-Cell Interaction
(2,000 rad) syngeneic or allogeneic spleen cells in 24-well culture
plates (25820; Corning Glass Works) in a volume of 2 ml at 37°C
for 5 d. Effector cells generated were assayed on 51Cr-labeled target
cells(spleen cells cultured for 48 hwith ConA, 5 ttg/ml). Percent
specific lysis was calculated as described (20). SEs in each group
were < 10%, andthese were excluded from the figures for simplicity.
To detect limiting effects of CTLprecursors, CTLinductionwas per-
formed in some experiments according to limiting dilution assay as
described(17). Briefly, graded numbers of lymph node cells were cul-
tured with 105 x-irradiated stimulating spleen cells in 96-well mi-
croplates in the absence of exogenous 1162, and 5 d later, "Cr-
labeled Con A blast target cells (10°) were directly added to each
culture well (six wells/group).
Production ofIL2 and Assay Systemfor IL2 Activity.
￿
A mixture
of lymph node andspleen cells (5 x 106) was cultured with 3 x
106 syngeneic or allogeneic stimulator spleen cells (2,000 rad) in
24-well culture plates (25820; CorningGlass Works) in avolume
of 1 ml (16-18). After incubation at 37°C in a humidified incu-
bator (5% C02) for 48 h, culture supernatants (SN) were har-
vested by centrifugation and stored at -20°C until use.
SN were assayed for IL2 activity according to their ability to
supportthe proliferation of theIL2-dependent Tcell line CTLIr2
(16-18). CTLL2 (10'/well) were cultured with the supernatant in
a volume of 0.2 ml in 96-well flat-bottomed microplates (25860;
CorningGlassWorks) for24 hat 37°C. Proliferation was assessed
by the uptake of [3H]TdR during a 4-h pulsing with 20 KBq
['H]TdR/well.
FITC-conjugated Antibodies.
￿
FITC was conjugated to GK1.5
mAbbyregular methods, followed by DE-52 (Whatman Biochem-
icals Ltd., England) ion exchange chromatography (21). The F/P
ratio of FITC/GK1.5 was 1.6. FITC-conjugated anti-Lyt-2 and
mouse anti-rat Ig antibodies were the products of Becton Dick-
inson Immunocytometry Systems, Mountain View, CA.
Immunofluorescence Staining and Flow Microfluorometry (FMF).
Thecell preparation and staining procedures were essentially the
same as describedpreviously (22). Briefly, 106 lymphoid cells were
incubated at 4°C for 30 min with FITC-conjugated antibodies,
washed twice, resuspended, and analyzed for fluorescence. These
procedures were performed in HBSS (without phenol red) con-
taining 0.1% BSA and0.1% sodium azide. FMF analysis wasper-
formed by using aFACStar (BectonDickinsonImmunocytometry
Systems). All data were collected by using log amplification, and
dead cells were rejected from analysis by additional staining with
propidium iodide.
Skin Grafting ofB6 Mice.
￿
B6 mice were engraftedon the flank
with twotail skin grafts, separatedby a host skin bridge, according
to an adaptation ofthemethod of Billingham and Medawar (23) .
Bandages were removed on day7, and thegrafts were scored daily
until rejection (defined as loss of > 80% of the grafted tissue).
Results
Responses ofLymphoid Cellsfrom bmlpresensitized B6 Mice
to bml Alloantigens upon the Stimulation with (bml x bm12)Fl
Cells. B6 mice were injected intravenously with 107 bml
spleen cells. 1 wk later, lymphnode cellswere obtained from
thesebml-presensitized or -unpresensitizedB6 mice andtreated
with anti-CD4 (GK1.5) or anti-CD8 (3.155) mAb plus C.
The resultant cells (CD8+ or CD4 subset of T cells) or un-
fractionated cellswere stimulated in vitrowith irradiated bml
or (bml x bm12) cells. Theresults ofTables 1 and2confirm
the fact (16, 17) that intravenous presensitization ofB6 miceB6 mice were injected intravenously with 107 bml spleen cells.
t Lymph node cells 1 wk after the bml presensitization were treated with anti-CD4 (GK1.5) or anti-CD8 (3.155) antibody plus C.
5 Lymph node cells (2 x 105/well) were cultured with 2,000-rad X-irradiated spleen cells (4 x 105/well) from the indicated strains of mice
for 4 d.
with bml alloantigens resulted in almost complete abroga-
tion of CD8+ T cell-mediated anti-bml proliferative (Table
1) and IIr2-producing (Table 2) capacities. It is also shown
that since the presensitization with bml cells did not affect
the responsiveness of CD4+ T cell subset, this subset of T
cells exhibited comparable magnitudes ofanti-bm12 responses
upon the stimulation with (bml x bml2)Ft cells in both
MLR and ID2 production.
Earlier studies from our laboratory have also demonstrated
that intravenous presensitization with bml cellsfailed to ab-
rogate CD8+ T cell-mediated anti-bml CTL responses in
contrast to the elimination of CD8+ Th (proliferative and
11,2-producing) capacities (16, 17). The results of Fig. 1
Table 2.
￿
Phenotype of Antioml x bm12)F,-reactive IL-2-producing T Cells in B6 Mice Presensitized with bmi Spleen Cells
Responding cells"
" Responding cells were the same as used in Table 1.
t Responding cells (5 x 106/well) were cultured with 2,000-rad X-irradiated spleen cells (3 x 106/well) from the indicated strains of mice for
2 d. Culture supernatants were submitted to IL-2 assay using CTLL-2 cells.
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confirm that potent anti-bml CTL responses are generated
in bulk cultures of spleen cells from bml-presensitized mice
(4 x 105/well). When the number of responding spleen cells
was reduced (2-1 x 105/well), the activity of anti-bml
CTL was appreciably or considerably weaker compared with
that obtained by using the same number of normal B6 re-
sponding cells. The results of Fig. 1 also show that in cul-
tures at the reduced respondingcell numbers, cells from bml-
presensitized mice induced slightly enhanced generation of
anti-bml CTL responses upon the stimulation with (bmi x
bml2)Ft cells when compared with responses induced upon
stimulation withbml cells, and that such an enhanced gener-
ation of anti-bml CTL was abrogated by elimination of
B6 mice
presensitized with: Treatment with:
[3H]TdR Uptake in
B6
IL-2 production
bml
cpm x 10 -'
after stimulation
(bml x
with:
bm12)Fl
B6 C 0.9 ± 0.1 11.7 ± 2.1 21.9 ± 1.8
Anti-CD4 + C ND 12.9 ± 0.3 7.9 ± 0.1
Anti-CD8 + C ND 2.1 ± 0.1 24.3 ± 0.7
bml C 0.5 ± 0.1 0.9 ± 0.1 20.3 ± 1.2
Anti-CD4 + C ND 0.9 ± 0.1 0.7 ± 0.1
Anti-CD8 + C ND 1.8 ± 0.1 22.8 ± 3.2
Table 1. Phenotype of
Responding
Antioml x bm12)F,-reactive
cells
Proliferating T Cells in B6 Mice Presensitized with bmi Spleen Cells
['H)TdR Uptake after stimulation witha
B6 mice
presensitized with:" Treatment with: B6 bml (bml x bm12)Ft
cpm x 10-3
B6 C 2.5 ± 0.2 29.4 ± 0.1 54.3 ± 1.6
Anti-CD4 + C ND 22.7 ± 1.4 28.5 ± 2.6
Anti-CD8 + C ND 2.9 ± 0.5 24.1 ± 4.3
bml C 3.3 ± 0.5 5.4 t 1.0 22.4 t 3.8
Anti-CD4 + C ND 3.5 ± 0.7 2.9 ± 0.4
Anti-CD8 + C ND 2.4 ± 0.3 24.2 t 2.250
40
30
20
10
0
Exp. t
￿
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Figure 1.
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Anti-bml CTL potentials in bml-presensitized B6 mice.
Lymph node cells from normal or bml-presensitized B6 mice were
untreated or treated with anti-CD4 antibody plus C. Graded num-
bers of these cells were cultured with 105 stimulating cells (indicated)
in 96-well microplates. Anti-bml CTL activity was assessed by add-
ing "Cr-labeled bml blast target cells directly into each well. The re-
sults are shown as the mean percent specific lysis of sextuplicate cul-
tures/group.
CD4+ T cells from responding cells before CTL induction.
These results suggest that the anti-bml CTL responses of
cells from the bml-presensitized B6 mice are reduced due to
elimination of anti-bml CD8+ Th cells, but these responses
may be augmented by introduction of an alternative CD4+
Th mechanism (anti-bm12 Th).
Anti-brnl Graft-rejecting Capacity Reduced by Intravenous Presen-
sitization Is Recovered by Engrafting (bm1 x bm12)F) Collateral
Grafts. B6 mice were presensitized intravenously with bml
cells, and 1 wk later, these bml-presensitized mice were en-
grafted with a bml graft (detecting graft) on the right flank
along with a collateral graft [bm12 or (bml x bm12)F)] on
the left flank. The results of Fig. 2 illustrate that (a) intrave-
nous presensitization o£ B6 mice with bml cells results in
the prolonged survival of bml skin grafts, which confirms
the previous report (17); and (b) such prolongation of bml
graft survival is prevented when B6 recipients are engrafted
with a (bml x bml2)Fi skin graft as a collateral graft. It
should be noted that engrafting bm12 skin grafts did not
prevent the prolongation of the bm1 skin graft survival, which
is induced by intravenous presensitization with bml cells.
Analysis of Anti-61 T Cell Responses in bm1presensitized
B6 Mice after (bml x bm12)Fl Skin Grafting. To determine
cellular mechanisms by which the prolongation ofbml skin
graft survival in bml-presensitized B6 mice is prevented by
engrafting (bml x bm12)Fl collateral grafts, we examined
anti-bml Th (proliferative and IL2-producing) (Tables 3 and
4), as well as CTL, activities (Fig. 3) in such B6 mice. B6
mice were presensitized with bml cells and engrafted with
bml skin grafts along with bm12 or (bml x bml2)Fl skin
grafts. The results demonstrate that lymphoid cells from bm1-
presensitized mice 10 d after the dual skin grafting exhibit
m
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Figure 2.
￿
(bml x bm12)Fl collateral skin grafting induces the re-
jection of bml skin graft in bmi-presensitized B6 mice. B6 mice 1
wk after bmi presensitization were engrafted with a detecting bmi
skin graft on the right flank and the indicated collateral skin graft on
the left flank.
only weak anti-bml proliferative (Table 3) and only marginal
11,2-producing (Table 4) activities. These results indicate that
potent anti-bml suppressive state is still maintained at the
CD8+ Th level, even after the dual skin-grafting.
Fig. 3 shows the generation ofCTL activityby spleen cells
obtained from the same mice as used in Tables 3 and 4. Ap-
preciable levels of anti-bml CTL responses generated in B6
mice receiving only bml presensitization regimen were at-
tenuated afterbml skin grafting (Fig. 3), which is consistent
with the previous results (17). Such a reduced anti-bml CTL
potential was also observed in bml-presensitized B6 mice that
were engrafted with a bm12 collateralskin graft (Fig. 3). How-
ever, when bml-presensitized mice were engrafted with a (bml
x bm12)Fl graft as a collateralgraft along with a bml skin
graft, spleen cells from these mice (10 d after the dual skin
grafting) produced potent anti-bml CTL activity. Such an
activity was comparable with or slightly higher than that
observed in unpresensitized normal B6 mice. These results
indicate that anti-bml CTL potential in bml-presensitized
mice, which is otherwise attenuated by bml skin grafting,
can be induced for its enhanced activation when the recip-
ient mice are engrafted with (bml x bm12)Fi collateral
grafts.
Re irement ofCD4+ T Subsetfor Preventing the Prolonga-
tion of bm1 Skin Graft Survivalin bmipresensitized, Dual Skin-
engrafted B6 Mice We next investigated whether CD4+ T
cells reactive with bm12 alloantigens are involved in the preven-
tion of prolonged bml graft survival in bml-presensitized
mice receiving a collateral (bml x bm12)F1 graft. Semi-
purified anti-CD4 (GK1.5) antibody was administered in vivo
at the dose of 100 wg/d, three times/wk to eliminate CD4+
T cells. This procedure was continued for 1-8 wk, and at
each stage, the efficacy of the procedure to deplete CD4+ T
cells was examined. Intraperitoneal injection ofanti-CD4 an-
Responders (treatment) StimWators Symbol n Presensab:ation collateral graft Deteetig graft
o normal lC) bmt -___ 10 (-) (-) bmi a (C)
a (a-CD4+C)
(bmlxbm12)Fl
bmi - a bml (-) bmi
O (a-CD44C) (bmlxbml2)Fl 0-0 9 bmi bm12 bm1
a presenaalxed (C) bml t-6 11 bml (bmtxbml2)Fl bmt a (C) (bmlxbml2)Fl
(a-CD4+C) bmi
0 (a-CD4+C) (bmlxbml2)FlTable 3.
￿
Anti-61proliferating T Cell Activity in bmlpresensitized B6 Mice 10 d after Dual Skin Grafting
' bml-presensitized B6 mice were engrafted with a bml-detecting graft and the indicated collateral graft.
t 10 d after the dual skin grafting, lymph node cells were harvested and stimulated with spleen cells (shown) in MLR.
tibody for 1 wk (three times) induced the depletion of>90%
CD4+ T cells (data not shown). Administration of the an-
tibody for an additional week (2 wk, six times) resulted
in almost complete elimination of CD4+ T cells without
affecting the CD8+ T cell subset (Fig. 4). The CD4+ T
cell-depleted statewas maintained by continued administra-
tion of the anti-CD4 antibody for 8 wk (data not shown).
bml-presensitized B6 mice were engrafted with bml and
bm12 or (bml x bml2)Ft collateral skin grafts, and the
Table 4.
￿
Anti-bml IL-2-producing T Cell Activity in bm1presensitized B6 Mice 10 d after Dual Skin Grafting
" Responding spleen cells were obtained from the same donor mice as used in Table 3.
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above protocol of anti-CD4 antibody administration was
started on the same day as the dual skin grafting (Fig. 5).
Theresults illustrate that in vivo administration of anti-CD4
antibody resulted in an appreciable prolongation of bml skin
graft survival under conditions in which bml-presensitized
B6 mice were engrafted with bml and (bml x bml2)Ft
skin grafts. These results indicate that the CD4+ T cell
subset is responsible forpreventing theprolongation ofbml
graft survival in the dual grafting model.
B6 mice
presensitized with:
Responding cells'
Detecting graft Collateral graft
['H]TdR
B6
Uptake after stimulation
bmI
with:$
BALB/c
cpm x 10-3
1.6 ± 0.4 24.9 ± 1.5 25.9 ± 1.6
bml (pooled) bml 2.0 ± 0.3 3.3 ± 0.5 26.2 ± 2.1
bml 1 bml bm12 2.2 ± 0.4 6.3 ± 0.8 26.0 ± 3.9
2 bml bm12 2.7 ± 0.6 7.4 ± 0.4 34.1 ± 2.0
3 bmI bm12 1.6 ± 0.1 3.6 t 0.5 23.8 ± 2.2
bml 1 bmI (bml x bml2)F, 2.2 ± 0.8 5.9 ± 0.6 28.8 ± 3.4
2 bml (bml x bm12)Fl 2.2 ± 0.2 5.9 ± 0.5 15.3 ± 1.4
3 bmI (bml x bm12)Fl 2.8 ± 0.5 9.1 ± 1.2 27.2 ± 1.9
4 bml (bml x bm12)Fl 2.5 ± 0.1 4.3 t 0.9 20.1 ± 1.0
B6 mice
presensitized with :
Responding cells""
Detecting graft Collateral graft
IL-2
B6
production after stimulation
bmI
with:
BALB/c
cpm x 10-'
1.7 ± 0.5 22.9 ± 2.1 17.1 ± 2.7
bmI (pooled) bml 1.1 ± 0.3 2.4 ± 0.2 16.7 ± 1.5
bmI 1 bmI bm12 1.2 ± 0.2 1.4 ± 0.1 14.3 ± 1.9
2 bmI bm12 1.3 ± 0.4 1.1 ± 0.1 10.1 t 1.6
3 bml bm12 1.2 ± 0.1 1.3 t 0.1 14.4 ± 0.8
bm11 bml (bml x bml2)Fl 1.3 ± 0.0 1.3 ± 0.2 15.6 ± 0.8
2 bmI (bml x bm12)Fl 0.6 ± 0.1 0.8 ± 0.1 13.8 t 1.2
3 bml (bml x bm12)Fi 1.9 t 0.3 3.2 ± 0.6 18.0 t 1.9
4 bmI (bml x bm12)Fl 1.4 ± 0.1 1.8 ± 0.2 15.3 ± 2.0100 Ant(-ben 1 Anti-KALB/c
2.5 5.0 10 20 2.5 5.0 10 20
Effector : target ratio
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Figure 3 .
￿
Generation of anti-bml CTL responses in bml-
presensitized B6 mice 10 d after dual skin grafting. A source of re-
sponding spleen cells was the same as used in Table IV Each group
of these cells was pooled and stimulated in vitro with bml or the
third party of BALB/c spleen cells and assayed on bml or BALB/c
(control) blast target cells .
Additional experiments were performed to investigate
whether the in vivo effect of anti-CD4 antibody administra-
tion is related to the suppression of anti-bml CTL genera-
tion. bml-presensitized B6 mice were engrafted with two
skin grafts [bml and (bml x bm12)Ft], and the adminis-
tration ofanti-CD4 antibody was started simultaneously with
the dual skin grafting . 10 d after the dual skin grafting, spleen
cells from these antibody-treated or untreated mice were tested
for their ability to generate anti-bml CTL responses . The
results of Fig. 6 demonstrate that administration in vivo of
m
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Figure 4 .
￿
Depletion of CD4+ T cells by in vivo administration of
anti-CD4 antibody. Semi-purified anti-CD4 (GK1 .5) antibody was in-
jected intravenously at the dose of 100 ug/day three times per week
for 2 wk . Lymph node and spleen cells from these antibody-treated
mice were submitted to FMF analyses.
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Figure 5 .
￿
Effect of (bml x bml2)Fl skin grafting is prevented by
in vivo administration of anti-CD4 antibody. B6 mice were unpresen-
sitized or presensitized with bml cells and engrafted with two skin
grafts as indicated. The injection of anti-CD4 antibody (100 pg/day,
three times/wk) was started on the same day as the dual skin
grafting .
anti-CD4 antibody prevents the generation ofanti-bm1 CTL
responses that are otherwise induced by spleen cells from bml-
presensitized B6 mice after two skin [bml and (bml x
bm12)F1] graftings. Taken collectively, these results indicate
that elimination of the CD4+ T cell subset results in the
prevention of the prolonged bml graft survival along with
inhibition of the generation of anti-bml CTL responses.
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Suppression of anti-brat CTL generation in bml-
presensitized, dual skin-engrafted B6 mice by injection of anti-CD4
antibody. B6 mice were unpresensitized or presensitized with bml
cells and engrafted with the indicated detecting and collateral grafts.
The injection of anti-CD4 antibody was started on the same day as
the dual skin grafting. Spleen cells from each group of mice were ob-
tained 10 d later.
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Male bml collateral skin grafting induces the rejection
of female bml grafts in bml-presensitized female mice. Unpresensi-
tized or bml-presensitized female B6 mice were engrafted with the
indicated collateral and detecting grafts.
Breakdown of Anti-bml CD8+ T Cell Tolerance by Intro-
duction ofanti-male Th Mechanism. We finally investigated
whether breakdown of anti-bml CD8+ T cell tolerance by
the introduction of an alternative Th mechanism can be gener-
alized, i .e ., breakdown of this tolerance is inducible by in-
troducing on a collateral (sensitizing) graft other cell surface
antigens than H-2 antigens. Female B6 mice were presensi-
tized with female bml cells, as has been performed in the
preceding experiments. These bml-presensitized and unpresen-
sitized B6 mice were engrafted with one or two skin grafts
that were ofB6 or bml, and male or female. The results are
summarized in Fig . 7 . The results demonstrate that (a) B6
male grafts were rejected in B6 female recipients although
the rejection was significantly delayed compared with that
of allogeneic bml (female) grafts ; (b) the survival of female
bml-detecting grafts was prolonged in bml-presensitized mice.
This was also the case when these recipient mice were en-
grafted with male B6 collateral grafts that themselves were
rejected in comparable time courses with those observed for
male B6-detecting grafts; (c) in contrast, engrafting male bml-
collateral grafts resulted in appreciably accelerated rejection
of female bml-detecting grafts. These results indicate that
(a) cell-cell interactions capable of mounting enhanced rejec-
tion responses are observed between T cells against various
types of antigens ; and (b) coexpression of these antigens on
a single graft is required for the induction of enhanced rejec-
tion responses .
A major issue in transplantation immunology is to ana-
lyze the mechanisms underlying cellular interactions involved
in in vivo responses to alloantigens . It has been shown that
allograft rejection results from interactions between Th and
effector T cells (e.g., CTL) of different phenotypes and of
different antigen specificities (4), although rejection of class
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I H-2-disparate grafts can be mediated by isolated CD8+ T
cell populations (24, 25) .
Another important goal is the establishment o£ immune
manipulations by which clonal elimination and/or functional
inactivation of alloantigen-reactive T cells are achieved . One
ofimmunobiological manipulations wouldbe to attempt nega-
tive regulation of immune responses by introduction of al-
loantigens via an intravenous route . This effect has been rec-
ognized as the beneficial one ofpretransplant DST in clinical
studies (5-10) . We have also demonstrated in animals studies
that CD8+ T cell responses to allo-class I H-2 or CD4+ T
cell responses to allo-class II H-2 antigens can be tolerized
by intravenous presensitization with cells expressing the cor-
responding alloantigens (16-18) . In considering that cellular
interactions between phenotypically andfunctionally distinct
subsets of T cells are involved in the rejection responses in
general, it would also be important to investigate how each
component ofT cell responses is mutually influenced by other
component(s) of these.
In the present study, we have investigated the effects of
cellular interactions on the induction and/or maintenance of
anti-allo-tolerance induced by the above-mentioned intrave-
nous presensitization regimen. The results demonstrate that
(a) intravenous presensitization ofB6 mice with class I H-2-
disparate bml cells results in the abrogation ofCD8+ Th cell
activity, leading to the prolongation ofbml graft survival ;
(b) when bml-presensitized mice were engrafted with bml
and (bml x bm12)Ft grafts, the survival of the bml graft
was not prolonged, but this graft was rejected along with
the (bml x bm12)F 1 graft ; (c) only marginal or potent anti-
bml CTL activity was generated by spleen cells from bml-
presensitized mice that were followed by engrafting onlybml
or two [bml and (bml x bm12)FiJ grafts, respectively ; (d)
the effect of engrafting collateral (bml x bm12)Ft grafts on
the generation ofCTL responses and inhibition ofprolonged
bml graft survival was abrogated by eliminating CD4+ T
cells able to react with bm12 alloantigens and to exert an
alternative (anti-bm12) Th activity ; and (e) a similar effect
ofcell-cell interaction to that observed between anti-bml (allo-
class I H-2) and anti-bm12 (allo-class II H-2) T cells was also
inducible by the interaction between anti-bml and anti-male
(non-H-2) responses .
The intravenous presensitization with bml cells did not
eliminate the total anti-bml CTL capacity. The reduced but
appreciable frequencies ofCTL precursors were detected in
lymph node and spleen cells (17) . Such CTL potential re-
maining in the bml-presensitized mice was suppressed along
with the engrafting ofbml skin grafts (17) . The present results
that bml presensitized, two graft [bml and (bml x
bm12)Ft]-engrafted mice were capable of developing en-
hanced anti-bml CTL responses indicated the involvement
of anti-bm12 responses in the generation of potent anti-bml
CTL responses . Thus, it is conceivable that CD4* T cell-
mediated anti-bm12 Th cell activity helped to activate anti-
bml CTL precursors remaining in thebml-presensitized mice
that are otherwise attenuated after the engrafting ofbm1 grafts
alone. It is also possible that such CTL activity contributed
to the rejection in vivo ofbrnl grafts. The results that elimi-nation of CD4+ T cells by administrating anti-CD4 anti-
body fails to generate these in vitro and in vivo effects could
support the above postulation.
Cell-cell interactions similar to those observed here were
originally reported by Rosenberg et al. (4). In their model,
CD4+ Th cells reactive to allo-class II H-2 generated help
for the activation of anti-Kbm6 or Qa1' CTL precursors that
represent helper-dependent effectors and fail to mature without
help from Th cells against other alloantigens. Thus, their
observations and ours illustrate the role of CD4+ Th cells
in positively regulating the activation of CTL responses to
other alloantigens in various combinations.
The present study should be discussed from two distinct
aspects. First, our results indicated that the activation ofanti-
bm12 CD4+ Th cells is not sufficient for enhanced induc-
tion ofanti-bml CTL, as well as prevention of the prolonged
bml graft survival, since the abovein vitro and in vivo effects
were induced when the recipient mice receiving bml grafts
were engrafted with (bml x bm12)Fi but not with bm12
grafts as collateral ones. Thus, an appropriate microenviron-
ment could be required under which the help of anti-bm12
CD4+ Th cells functions to efficiently activate anti-bml
CTL precursors. It is conceivable that (bml x bm12)Ft cells
expressing both bml and bm12 alloantigens are responsible
for this cell-cell interaction process. It has been established
that the stimulation of Th cells, especially priming of virgin
Th cells, requires the participation ofAPC expressing helper
determinants (1, 2). Therefore, in this model, (bml x
bml2)Ft cells that express helper (bm12) determinants and
bml CTL antigens, and possess APC functions, i.e., Ia+ cells
such as Langerhans cells, might be visualized as operating
for the cellular interaction. It may also be possible that once
anti-bm12 Th cells are activated to produce IFN-y capable of
inducing the expression of la antigens on Ia cells (26-28),
skin cells rendered Ia+ by IFN-y (keratinocytes) might pro-
vide the function for stimulating both Th cells and CTL.
Another important aspect is concerned with the physio-
logic relevance of the present study. Since DST is attempted
by using cells from the donor that provides the graft, the
situation made in the present study, i.e., the activation of
anti-class I CTL by anti-class II CD4+ Th cells, would be
unrealistic. Nevertheless, it would be ofvalue to consider the
clinical relevance of the present observations based on cel-
lularinteractions. Although only described for skin (29), the
existence of tissue- or organ-specific histocompatibility an-
tigens has been suggested (30). It couldbe that some of such
tissue- or organ-specific histocompatibility antigens function
as helper determinants, as has been observed for bm12 al-
loantigens. Thus, the existence of tissue- or organ-specific
histocompatibility antigens is ofpractical importance when
the induction ofdonor-specific tolerance attempts to use cells
ofone tissue type, but organs ofanother tissue type are trans-
planted. The fact that the coexpression on a graft of male-
specific antigen as a model of non-H-2 antigen induced en-
hanced rejection responses could support this notion.
The present results illustrate that the induction and/or main-
tenance of tolerance to a given alloantigen is influenced by
cellular interactions between T cellsagainst that antigen and
other antigens coexpressed on a graft. Our recent study (Hori,
S., S. Kitagawa, S. Sato, T Hamaoka, and H. Fujiwara,
manuscript in preparation) also revealed that the effect of in-
travenous presensitization is modulated by cellular interac-
tions between anti-class I and -class II H-2 T cells when
class I- and class II-disparate cells are used for the intrave-
nous presensitization. Taken together, these approaches could
contribute to a better understanding of complex cellular in-
teractions involved in graft rejection responses in vivo, and
provide the validity for attempting to apply such studies to
clinical transplantation immunology.
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